Evidence map›Paper›PMID 14660751›Full record

ArticleThe Journal of clinical investigation2003

Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair.

Myriam Alcalay, Natalia Meani, Vania Gelmetti, Anna Fantozzi, Marta Fagioli, Annette Orleth, Daniela Riganelli, Carla Sebastiani, Enrico Cappelli, Cristina Casciari and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 244 citations in OpenAlex.

  1. Targeting Runx1 Slows Cyst Growth in Autosomal Dominant Polycystic Kidney Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Myriam AlcalayDepartment of Experimental Oncology, European Institute of Oncology, Milan, Italy. alcalay@ifom-firc.it
Natalia Meani
Vania Gelmetti
Anna Fantozzi
Marta Fagioli
Annette Orleth
Daniela Riganelli
Carla Sebastiani
Enrico Cappelli
Cristina Casciari
Maria Teresa Sciurpi
Angela Rosa Mariano
Simone Paolo Minardi
Lucilla Luzi
Heiko Muller
Pier Paolo Di Fiore
Guido Frosina
Pier Giuseppe Pelicci
University of Perugia · ITEuropean Institute of Oncology · ITIFOM · ITAlleanza Contro il Cancro · ITCasa Sollievo della Sofferenza · ITIstituto Giannina Gaslini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myelogenous leukemias (AMLs) are genetically heterogeneous and characterized by chromosomal rearrangements that produce fusion proteins with aberrant transcriptional regulatory activities. Expression of AML fusion proteins in transgenic mice increases the risk of myeloid leukemias, suggesting that they induce a preleukemic state. The underlying molecular and biological mechanisms are, however, unknown. To address this issue, we performed a systematic analysis of fusion protein transcriptional targets. We expressed AML1/ETO, PML/RAR, and PLZF/RAR in U937 hemopoietic precursor cells and measured global gene expression using oligonucleotide chips. We identified 1,555 genes regulated concordantly by at least two fusion proteins that were further validated in patient samples and finally classified according to available functional information. Strikingly, we found that AML fusion proteins induce genes involved in the maintenance of the stem cell phenotype and repress DNA repair genes, mainly of the base excision repair pathway. Functional studies confirmed that ectopic expression of fusion proteins constitutively activates pathways leading to increased stem cell renewal (e.g., the Jagged1/Notch pathway) and provokes accumulation of DNA damage. We propose that expansion of the stem cell compartment and induction of a mutator phenotype are relevant features underlying the leukemic potential of AML-associated fusion proteins.

Indexed as

DNA RepairGene Expression RegulationCalcium-Binding ProteinsCell DifferentiationCore Binding Factor Alpha 2 SubunitHumansIntercellular Signaling Peptides and ProteinsJagged-1 ProteinMembrane ProteinsMutationNeoplasm ProteinsOligonucleotide Array Sequence AnalysisOncogene Proteins, FusionPhenotypeProteinsRUNX1 Translocation Partner 1 ProteinAML1-ETO fusion protein, humanCalcium-Binding ProteinsCore Binding Factor Alpha 2 SubunitIntercellular Signaling Peptides and ProteinsJAG1 protein, humanJag1 protein, mouseJagged-1 ProteinMembrane ProteinsNeoplasm ProteinsOncogene Proteins, FusionPLZF-RARalpha fusion protein, humanpromyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinProteinsRUNX1 Translocation Partner 1 ProteinSerrate-Jagged ProteinsTranscription FactorsTretinoin

Identifiers

PMID14660751
PMCPMC281638
OpenAlexW2139460080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.